# Rewiring Dendritic Cell Immunity: The β-Catenin–TIM-3 Axis as a Target to Improve DC Cancer Vaccines

## TL;DR

This paper reviews how the β-catenin–TIM-3 pathway in dendritic cells weakens cancer vaccines and suggests targeting this pathway to improve immune responses.

## Contribution

The paper introduces the β-catenin–TIM-3 axis as a novel regulatory mechanism limiting DC vaccine efficacy and proposes strategies to counteract it.

## Key findings

- β-catenin signaling in dendritic cells induces TIM-3, which suppresses CD8 T cell activation.
- Targeting the β-catenin–TIM-3 axis could enhance DC-based vaccines and combination immunotherapies.
- This pathway may explain limited success of current DC vaccines in solid tumors.

## Abstract

Cancer vaccines rely on dendritic cells (DCs) to prime tumor-killing CD8 T cells, but tumors often develop mechanisms to suppress DC function. Emerging evidence shows that a signaling molecule called β-catenin in DCs induces the checkpoint receptor T cell immunoglobulin and mucin-domain containing-3 (TIM-3), which acts as a “brake” and reduces DCs’ ability to stimulate T cells. This review outlines how the β-catenin–TIM-3 axis undermines vaccine responses and highlights strategies to boost CD8 T cell immunity and improve combination therapies with immune checkpoint blockade (ICB).

The success of cancer vaccines relies on the ability of dendritic cells (DCs) to efficiently prime cytotoxic CD8 T cell responses against tumors. However, in solid tumors this process is often undermined by tumor-driven immunosuppression and intrinsic defects in DC activation. Among the signaling pathways implicated in DC dysfunction, β-catenin signaling has emerged as a key regulator of immune tolerance in DCs. In parallel, inhibitory receptors such as PD-L1 and TIM-3 on DCs have been recognized as critical DC-intrinsic brakes on CD8 T cell priming and on responses to immune checkpoint blockade (ICB). Recent work has identified a DC-intrinsic immunoregulatory circuit in which β-catenin activation in DCs—particularly in cross-presenting cDC1s—induces expression of TIM-3, thereby suppressing CD8 T cell cross-priming and limiting anti-tumor CD8 T cell immunity. This β-catenin–TIM-3 axis represents a previously underappreciated layer of negative regulation that may help explain, at least in part, the limited efficacy of many current DC-based cancer vaccines. In this review, we examine how β-catenin activation in DCs, particularly in cDC1s, induces TIM-3 and related inhibitory programs that suppress cross-priming of tumor antigen-specific CD8 T cells and constrain the efficacy of DC-based vaccines. We further discuss how selectively targeting this β-catenin–TIM-3 checkpoint axis—alone or together with PD-L1 and other β-catenin–linked receptors—could restore DC function and inform rational combinations of DC-based vaccination with ICB and other T cell-based immunotherapies.